Sulbutiamine for Health & Longevity

Evidence Review created on 09/25/2026 using AI4L / Opus 5.5

Also known as: Arcalion, Enerion, Sulbuxin, Bisibutiamine, Isobutyrylthiamine Disulfide, O-Isobutyrylthiamine Disulfide, Sulbuthiamine, Sulbutiamin, Sulbutiamina, Sulbutiaminum

Motivation

Sulbutiamine is a laboratory-made form of vitamin B1 (thiamine): two vitamin B1 molecules joined by a sulfur bridge. This change makes it fat-soluble, so it enters the brain far more easily than ordinary vitamin B1, which is used by the body to turn food into energy. It draws interest from health-focused adults for its possible effects on mental energy, focus and memory.

The compound was created in Japan in the 1960s to treat vitamin B1 deficiency and was later sold in France and other countries as a medicine for persistent weakness and mental fatigue. Today it is also sold online as a focus and energy supplement, even though it is not approved as a medicine in the United States and regulators there question its legal status as a supplement. Most of its human research is decades old, small and mixed in its results.

This review examines what the human, animal and laboratory evidence shows about sulbutiamine’s effects on fatigue, brain function and nerve health, what is known about its safety, and how it is used in practice, with a view to its role in long-term health.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

This section lists overview articles and expert commentary that discuss sulbutiamine in depth.

• Role of the Synthetic B1 Vitamin Sulbutiamine on Health - Starling-Soares et al., 2020

  The most complete narrative review of sulbutiamine’s chemistry, brain thiamine effects, human trials and side effects, concluding that randomized controlled trials are still largely missing.

• Pharmacologic and therapeutic features of sulbutiamine - Van Reeth, 1999

  An older pharmacology review framing sulbutiamine as an anti-asthenia drug (asthenia: persistent physical and mental fatigue), summarizing animal models and the early French clinical experience behind its prescription use.

• On the specific treatment of asthenic states: focus on sulbutiamine - Bykov & Bekker, 2022

  A Russian-language review (English abstract) of sulbutiamine’s pharmacokinetics, anti-fatigue mechanisms and clinical use as Enerion, comparing it with other anti-fatigue drugs; its favorable conclusions rest largely on small studies.

• Sulbutiamine in Dietary Supplements - Operation Supplement Safety

  The U.S. Department of Defense supplement-safety program summarizes sulbutiamine’s regulatory status, reported side effects and label pseudonyms, and explains why it sits on the military’s prohibited ingredient list.

No dedicated sulbutiamine content was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension or Lifespan.io; Life Extension only reproduces a benfotiamine abstract that names sulbutiamine in passing. A likely reason is that sulbutiamine is a niche nootropic with a thin, mostly decades-old evidence base and no lawful status as a U.S. dietary supplement ingredient, placing it outside these platforms’ usual coverage. Only four items give a high-level overview of sulbutiamine; narrower papers, such as anti-doping laboratory reports, were left out rather than used to pad the list to five.

Grokipedia

• Sulbutiamine

  A structured encyclopedic overview of sulbutiamine’s chemistry, pharmacology, medical uses, adverse effects and history, useful as a quick orientation before reading the primary studies.

Examine

• Sulbutiamine benefits, dosage, and side effects

  Examine’s page notes that human studies used 400 mg daily, that the optimal dosing regimen is unknown, and that its database holds only one small trial (30 participants).

ConsumerLab

No ConsumerLab article on sulbutiamine exists. ConsumerLab has not tested sulbutiamine products, likely because it is not a lawful dietary ingredient in the United States.

Systematic Reviews

No systematic reviews or meta-analyses for Sulbutiamine were found on PubMed as of September 25, 2026.

Neither the claimed benefits (fatigue, cognition, nerve function) nor the principal risks are represented by a systematic review or meta-analysis.

Mechanism of Action

Sulbutiamine is two thiamine (vitamin B1) molecules opened and joined by a disulfide (sulfur–sulfur) bridge, each carrying an isobutyryl ester group (a small fat-like chemical side chain). Being fat-soluble, it diffuses across the gut wall and the blood–brain barrier (the protective filter around the brain) without thiamine’s slow transporters.

• Conversion to active vitamin B1: Inside cells the glutathione and thioredoxin systems (the cell’s main antioxidant repair systems) cut the disulfide bridge and the ester groups are removed, releasing thiamine (Folda et al., 2025). Thiamine becomes thiamine diphosphate, the coenzyme (enzyme helper) of energy-producing enzymes in mitochondria (the cell’s power plants), and thiamine triphosphate, which rises in rat brain after sulbutiamine (Bettendorff et al., 1990).
• Brain signaling: In rats, repeated dosing raised cortical dopamine D1 receptors (receptors for the motivation messenger dopamine) and lowered kainate receptors (receptors for the excitatory messenger glutamate) (Trovero et al., 2000); in mice it raised choline uptake in the hippocampus (the memory center) (Micheau et al., 1985). The rat work came from Key-Obs, a contract research firm; funding is undisclosed.
• Competing explanations: One view attributes effects to better brain thiamine supply, so thiamine-replete people gain little; the other to disulfide-specific antioxidant (electron-transfer) or receptor actions (Volvert et al., 2008).
• Pharmacology: Labeling reports peak blood thiamine at 1–2 hours and a half-life of about 5 hours. It reaches brain, kidney and red blood cells, is not receptor-selective, and has no known CYP (cytochrome P450, liver drug-metabolizing enzyme) pathway; metabolites leave via urine.

Historical Context & Evolution

Sulbutiamine was synthesized in Japan in the mid-1960s by Tanabe Pharmaceutical as one of several fat-soluble thiamine derivatives designed to treat beriberi (the nerve and heart disease of vitamin B1 deficiency), which remained a public-health problem in rice-dependent postwar Japan (Starling-Soares et al., 2020). Ordinary thiamine is poorly absorbed at high oral doses; fat-soluble derivatives solved this.

• Shift to fatigue medicine: In the 1970s Laboratoires Servier launched sulbutiamine in France as Arcalion, an anti-asthenia drug, and Egis later marketed it as Enerion in Eastern Europe and Russia. Early Italian and French clinical reports described improvement in neurasthenic syndromes (chronic nervous exhaustion) (Balestreri et al., 1979).
• Research phase: Animal studies in the 1980s–2000s reported memory and wakefulness effects, and trials in depression, Alzheimer’s disease and diabetic nerve damage followed, much of it while Servier marketed the drug and with funding largely undisclosed. The largest placebo-controlled fatigue trial, in 1999, found no lasting benefit (Tiev et al., 1999), while uncontrolled studies continued to report improvement. The disagreement has never been resolved by an independent trial.
• Nootropic era: From the 2000s, online vendors sold it as a focus and motivation supplement, and anti-doping laboratories began detecting it in athletes. In December 2019 the U.S. Food and Drug Administration placed it on its Dietary Supplement Ingredient Advisory List, questioning its legal status as a supplement ingredient.
• Current standing: Recent work uses laboratory and animal models of stroke, diabetic damage and cancer; human evidence remains limited to older trials.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: each human clinical endpoint rests on a single randomized trial, open-label or uncontrolled series, or trials that conflict, and none has been replicated across controlled trials.

Medium 🟩 🟩

Memory and daily function as an add-on in early Alzheimer’s disease

In a multicenter double-blind randomized trial in early-to-moderate Alzheimer’s disease, sulbutiamine (400–600 mg/day) given alone for three months and then combined with donepezil (an acetylcholinesterase inhibitor, a drug that slows breakdown of the memory messenger acetylcholine) improved episodic memory (memory for events) and daily activities, whereas donepezil plus placebo saw episodic memory decline (Ollat et al., 2007). Rodent memory studies support a cholinergic (acetylcholine-based) mechanism. The trial was small and unreplicated, and its lead author also co-authored contract-research animal studies.

Magnitude: Episodic memory and daily-activity scores improved with sulbutiamine plus donepezil over three months, while episodic memory declined with donepezil plus placebo; the published abstract reports no outcome figure.

Nerve function in diabetic polyneuropathy

In an open-label randomized trial of 30 adults with type 2 diabetes and polyneuropathy (nerve damage in the limbs), six weeks of sulbutiamine improved nerve conduction velocity (the speed of electrical signals along nerves) and muscle response amplitude compared with no treatment (Kiew et al., 2002). Symptom scores did not differ between groups, and blood glucose was unchanged, so the effect is not explained by better sugar control. There was no placebo or blinding.

Magnitude: Median and peroneal nerve conduction velocity and muscle action potential improved versus untreated controls after 6 weeks (all p<0.001, where p is the probability the difference arose by chance); the abstract reports no absolute change figure.

Faster recovery of drive during depression treatment

In an eight-week double-blind placebo-controlled trial in hospitalized patients with major depression receiving clomipramine (a tricyclic antidepressant, an older antidepressant class), adding sulbutiamine 600 mg/day did not improve depression scores but reduced psycho-behavioral inhibition (slowed thinking, low drive and social withdrawal) (Lôo et al., 2000). Patients reported less disability in social, work and family life. The trial shares a co-author (Ollat) with other manufacturer-era studies.

Magnitude: Patients on sulbutiamine scored significantly less disabled than placebo on all Sheehan Disability Scale (a validated function questionnaire) domains at 4 weeks, with no difference in depression scores; the abstract reports no outcome figure.

Bladder control in children with bedwetting ⭕️ Not Central to Health & Longevity

A 2026 randomized trial in 450 children and adolescents with primary nocturnal enuresis (lifelong bedwetting) compared sulbutiamine 100 mg/day, imipramine (a tricyclic antidepressant used for bedwetting) and both together over six months (Ahmed Mahmoud et al., 2026). Sulbutiamine produced more complete responses and fewer relapses than imipramine. This bears on pediatric bladder control and arousal from sleep, not on adult health or longevity. There was no placebo arm.

Magnitude: Complete response 52.7% with sulbutiamine versus 37.3% with imipramine; relapse 28.7% versus 43.6% at six months.

Low 🟩

Relief of fatigue and weakness ⚠️ Conflicted

Reports without placebo after infection (Shah, 2003, commercial cohort), in multiple sclerosis (Sevim et al., 2017) and after concussion versus piracetam (Levin & Slizkova, 2007) describe relief, but a 326-patient placebo-controlled trial found none at 28 days (Tiev et al., 1999). Net reading: controlled data do not confirm lasting relief.

Magnitude: No difference from placebo on a validated fatigue scale at 28 days; uncontrolled studies reported 51.7% complete symptom resolution and a Fatigue Impact Scale drop from 77 to 60.5 over 60 days.

Erectile function in psychogenic erectile dysfunction

In an uncontrolled 30-day study of 20 men with psychologically driven erectile dysfunction, sulbutiamine (as Enerion) improved erectile function in 16 men (Dmitriev et al., 2005). There was no placebo group, and the finding has not been replicated.

Magnitude: International Index of Erectile Function (a validated questionnaire) score rose from 17.5 to 24.8 in responders over 30 days.

Speculative 🟨

Brain protection after stroke-like injury

In human nerve-like cells deprived of oxygen and glucose and in a rat stroke model, sulbutiamine preserved neurons and reduced deficits (Meng et al., 2025). The basis is laboratory and animal data only.

Cellular antioxidant defense

Cell studies show sulbutiamine protects against oxidative stress and activates the Nrf2 pathway (a master switch for antioxidant genes) (Folda et al., 2025). The basis is mechanistic cell work only.

Protection against diabetic kidney and testicular damage

In diabetic rats, sulbutiamine reduced kidney injury (Ghaiad et al., 2023) and preserved testosterone and sperm counts (Abdelmonem et al., 2024). The basis is animal data only.

Anticancer activity ⚠️ Conflicted

Sulbutiamine slowed cancer cell growth in dishes but did not shrink tumors in mice (Jonus et al., 2020). The basis is laboratory and animal data only. No anticancer effect is established in living animals.

Activity against microsporidia parasites ⭕️ Not Central to Health & Longevity

In the laboratory, sulbutiamine disabled a key energy enzyme of Encephalitozoon intestinalis, a gut parasite (García-Torres et al., 2018). This bears on parasitic infection, not longevity; the basis is test-tube data only.

Benefit-Modifying Factors

• Genetic variants in thiamine transport: Variants in SLC19A2 and SLC19A3 (genes encoding the cell’s thiamine transporters) impair thiamine uptake; sulbutiamine’s fat-solubility bypasses these transporters, so carriers could theoretically benefit more than from ordinary thiamine. No human study has tested this.
• Baseline thiamine status: Low whole-blood thiamine diphosphate, heavy alcohol use, loop diuretics (potent fluid-removing drugs such as furosemide), bariatric surgery (weight-loss surgery) or poorly controlled diabetes raise the chance of benefit; in thiamine-replete people, extra thiamine delivery may add little.
• Sex differences: In the largest fatigue trial, only women on 600 mg/day had less fatigue at day 7, and the effect had faded by day 28 (Tiev et al., 1999). No other sex-specific data exist.
• Pre-existing conditions: In multiple sclerosis, fatigue improved only in patients already on disease-modifying therapy (drugs that slow multiple sclerosis) (13 of 23) and in none of 5 untreated patients (Sevim et al., 2017). Alzheimer’s benefit was seen alongside donepezil (Ollat et al., 2007).
• Age: Older adults more often have marginal thiamine status and cognitive decline, the settings where trials showed signals; no trial has tested sulbutiamine in healthy older adults.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event data come from single placebo-controlled trials, one uncontrolled cohort and case reports, and no adverse event has been replicated as a controlled endpoint.

Medium 🟥 🟥

No risk reaches Medium: the two placebo-controlled trials, in fatigue and depression, found adverse-event rates similar to placebo, and the remaining human data are an uncontrolled cohort, one randomized trial without placebo, product labeling and a single case report.

Low 🟥

Nausea, headache and diarrhea

Mild digestive upset and headache are the most reported adverse events and resolve on stopping. An uncontrolled 1,772-patient cohort recorded side effects in 0.6%, half of them nausea (Shah, 2003); a placebo-controlled trial found similar event rates with placebo (Tiev et al., 1999, as tallied in a 2020 narrative review).

Magnitude: 0.6% (10 of 1,772) over 15 days in the cohort, 5 of them nausea; in the 326-patient trial, 15 sulbutiamine-treated and 12 placebo-treated patients reported events.

Skin rash and allergic reactions

French Arcalion labeling lists skin rash as an uncommon adverse event and warns that the tablets’ orange-yellow S dye (E110, an azo food coloring) can cause allergic reactions (Arcalion patient leaflet). The side-effect tally of a 2020 review records no rash in published studies, so the evidence is post-marketing only.

Magnitude: Labeling classes rash as uncommon, occurring in between 1 in 1,000 and 1 in 100 users; no published study reports a case.

Insomnia, agitation, tremor and palpitations

Sulbutiamine’s wake-promoting action can disturb sleep, especially with evening doses. Isolated insomnia and tremor cases appear in an uncontrolled cohort (Shah, 2003), agitation and palpitations among placebo-controlled trial events (as tallied in a 2020 review), and all four in the Operation Supplement Safety monograph.

Magnitude: Insomnia and tremor each in 1 of 1,772 (about 0.06%) in the uncontrolled cohort; headache or insomnia in 3 of 40 (8%) patients on sulbutiamine alone in a randomized Alzheimer’s trial (Ollat et al., 2007, as tallied in a 2020 review).

Mood destabilization and compulsive use

A case report describes a man with bipolar disorder who escalated sulbutiamine intake compulsively, which disrupted his psychiatric care (Douzenis et al., 2006). Dopamine receptor changes in rodents offer a plausible mechanism.

Magnitude: Not quantified in available studies. Only a single case report exists, so no incidence figure is available.

Confounded anti-doping screens

A sulbutiamine metabolite appears at the same point as a metabolite of boldenone (an anabolic steroid) in standard screening, which can trigger suspicion and follow-up testing (Sobolevsky & Rodchenkov, 2010). Sulbutiamine itself is not on the World Anti-Doping Agency Prohibited List.

Magnitude: About 100 of roughly 16,000 Russian doping-control urine samples (about 0.6%) contained sulbutiamine in 2009, most above 500 ng/mL.

Speculative 🟨

Tolerance through dopamine receptor adaptation

Repeated dosing raised dopamine D1 receptor density in rat cortex (Trovero et al., 2000), suggesting possible tolerance. The basis is animal data and anecdotal user reports.

Unknown long-term safety

Human exposure data extend to about six months in adults with Alzheimer’s disease and in children. Effects of multi-year use are unstudied; the basis is absence of data only.

Risk-Modifying Factors

• Genetic polymorphisms: No pharmacogenetic data exist. Because no CYP enzyme pathway is known, common drug-metabolism variants (for example CYP2D6, a liver enzyme that clears many drugs) are unlikely to change exposure.
• Baseline biomarkers: Poor baseline sleep, elevated anxiety scores or reduced kidney function (estimated glomerular filtration rate, eGFR, a kidney-filtering estimate, below 60 mL/min) may raise vulnerability to overstimulation or accumulation of thiamine metabolites; this is untested.
• Sex differences: No sex differences in adverse events have been reported; pregnancy and breastfeeding safety data are absent.
• Pre-existing conditions: Bipolar disorder, a history of substance misuse, panic disorder or chronic insomnia increase the risk of mood destabilization, compulsive use or sleep disruption.
• Age: Older adults with fragile sleep or several medications may be more sensitive to agitation; in an Alzheimer’s trial at 400–600 mg/day, 3 of 40 patients on sulbutiamine alone reported headache or insomnia (Ollat et al., 2007).

Key Interactions & Contraindications

No formal drug-interaction studies exist; the entries below rest on product labeling, mechanism, trial co-administration and case reports.

Prescription drug interactions:

• Mood stabilizers and antipsychotics (drugs that control mood swings and psychosis; lithium, valproate, quetiapine): Caution. Sulbutiamine use undermined bipolar treatment in a case report (Douzenis et al., 2006). Mitigation: use in bipolar disorder is generally avoided unless the treating psychiatrist is involved.
• Stimulant and dopaminergic drugs (drugs that raise alertness or dopamine activity; methylphenidate, amphetamine, modafinil, bupropion): Monitor. Additive stimulation may cause insomnia, agitation or raised heart rate. Mitigation: morning-only dosing and a lower sulbutiamine dose.
• Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine): Monitor. Co-administered sequentially in an Alzheimer’s trial (Ollat et al., 2007); additive cholinergic effects (nausea, headache) are possible. Mitigation: agents are typically introduced one at a time, as in that trial.
• Antidepressants (drugs that treat depression; clomipramine, sertraline, venlafaxine): Monitor. Combined with clomipramine in a trial without excess events (Lôo et al., 2000); monitoring for activation or agitation is the usual precaution.
• Hypnotics and sedatives (sleep and calming medications; zolpidem, lorazepam): Caution. Opposing effects may reduce sleep-aid efficacy. Mitigation: sulbutiamine dosing is kept before midday.
• Neuromuscular blocking agents (muscle relaxants used in general anesthesia; rocuronium, vecuronium, succinylcholine): Caution. French Arcalion labeling warns that thiamine may increase their effect (Arcalion patient leaflet). Mitigation: disclosing sulbutiamine use to the anesthetist before surgery allows dosing adjustment.
• Diuretics (fluid-removing drugs; furosemide, hydrochlorothiazide): Monitor. Labeling notes diuretics increase urinary thiamine loss, which may reduce sulbutiamine’s thiamine contribution. Mitigation: thiamine status is checked in long-term diuretic users.

Over-the-counter medication interactions:

• Decongestants (nasal-congestion relievers; pseudoephedrine, phenylephrine): Caution. Additive stimulation may cause palpitations or insomnia. Mitigation: same-day combination is usually avoided.
• Sedating antihistamines (allergy and sleep-aid drugs that cause drowsiness; diphenhydramine, doxylamine): Monitor. Opposing effects blunt both drugs. Mitigation: doses are typically separated by at least 8 hours.

Supplement interactions:

• Stimulant-containing blends (caffeine, higenamine, hordenine, synephrine): Caution. Additive stimulation may cause palpitations, anxiety and insomnia. Mitigation: caffeine is typically kept under 200 mg on dosing days.
• Cholinergic supplements (products that boost acetylcholine; alpha-GPC, citicoline, huperzine A): Monitor. Additive cholinergic effects may cause headache or nausea. Mitigation: agents are typically introduced one at a time.
• Other thiamine forms (thiamine hydrochloride, benfotiamine): Monitor. Additive thiamine supply is low-risk but usually redundant.

Other interactions:

• Alcohol: Caution. Alcohol impairs thiamine absorption and sleep; sulbutiamine does not offset intoxication. Mitigation: alcohol-free dosing days reduce this.
• Anti-doping testing: Monitor. Sulbutiamine can confound steroid screens. Mitigation: tested athletes typically disclose use or stop it before competition.

Populations who should avoid Sulbutiamine:

• Bipolar I or II disorder (DSM-5, the standard psychiatric diagnostic manual) or any history of mania or hypomania (a milder form of mania)
• Current or past substance use disorder (DSM-5)
• Pregnancy (any trimester) and breastfeeding
• Children and adolescents under 18, outside supervised clinical use
• Chronic insomnia (Insomnia Severity Index, a validated questionnaire, score ≥15)
• U.S. service members (Department of Defense prohibited ingredient) and competitors subject to anti-doping testing
• Known hypersensitivity to sulbutiamine or thiamine derivatives

Risk Mitigation Strategies

• Morning and midday dosing only: Doses taken with breakfast and lunch, none after 2 p.m., limit insomnia and evening agitation given the roughly 5-hour half-life.
• Start low and titrate: Starting at 200 mg/day for 3–7 days before increasing to 400–600 mg/day reduces nausea, headache and overstimulation.
• Dose ceiling: Staying at or below 600 mg/day, the highest dose studied in trials, avoids untested exposure and escalation toward compulsive use.
• Time-limited courses: Courses of 4–8 weeks, matching trial durations, followed by at least 2 weeks off, limit tolerance and unknown long-term risks.
• Psychiatric screening: A mood-disorder history check before starting and weekly self-rating of sleep need and irritability detect emerging hypomania or compulsive use early.
• Avoid stimulant combinations: Using single-ingredient products and keeping caffeine under 200 mg/day prevents additive palpitations, anxiety and insomnia.
• Verified product quality: Pharmaceutical-grade products or a batch certificate of analysis (purity ≥98%) reduce the risk of mislabeled or contaminated powders.

Therapeutic Protocol

• Pharmaceutical protocol: French prescribing practice with Arcalion (Laboratoires Servier) uses 400–600 mg/day orally (two to three 200 mg tablets) at breakfast and lunch, in courses of about four weeks for asthenia.
• Nootropic protocol: Nootropic writers such as David Tomen (Nootropics Expert sulbutiamine profile) describe 400–1,000 mg/day, split morning and early afternoon, cycled 5 days on and 2 off; doses above 600 mg/day are untested in trials.
• Thiamine-repletion alternative: Where the aim is correcting low thiamine rather than brain stimulation, clinicians often use thiamine hydrochloride or benfotiamine instead, which raise blood thiamine without sulbutiamine’s central stimulation.
• Time of day: Morning and midday administration with a meal is standard; evening doses risk insomnia. A fat-containing meal may aid absorption of this fat-soluble compound, though this is untested.
• Half-life: Product labeling reports peak blood thiamine at 1–2 hours and elimination half-life of about 5 hours; brain thiamine phosphate stores turn over more slowly.
• Single versus split dosing: Split doses (two or three daily) match the short half-life; the multiple sclerosis study used 400 mg once daily (Sevim et al., 2017).
• Genetic factors: No pharmacogenetic dosing guidance exists; people with known thiamine-transporter (SLC19A2 or SLC19A3) variants are managed by specialists, typically with high-dose thiamine.
• Sex differences: No sex-specific dosing exists; the only sex signal is a transient day-7 fatigue effect in women at 600 mg/day (Tiev et al., 1999).
• Age: Older adults typically start at 200 mg/day given sleep sensitivity; Alzheimer’s trial patients used 400–600 mg/day.
• Baseline biomarkers: Low whole-blood thiamine diphosphate or a raised transketolase activity coefficient (a red-cell enzyme test of thiamine function) signals deficiency, the setting most likely to respond.
• Pre-existing conditions: Diabetic neuropathy (Kiew et al., 2002) and multiple sclerosis fatigue (Sevim et al., 2017) studies used 400 mg/day for 6–8 weeks; bipolar disorder excludes use.

Discontinuation & Cycling

• Short-term use: Sulbutiamine is a short-course intervention; trials lasted 4 weeks to 6 months, and French prescribing practice uses courses of about four weeks. It is not intended as a lifelong daily supplement.
• Withdrawal effects: No formal withdrawal syndrome is documented. In monkeys, sleep and wakefulness changes reversed 2–5 days after stopping (Balzamo & Vuillon-Cacciuttolo, 1982); transient low energy is anecdotally reported.
• Tapering: Tapering is not pharmacologically required at 400–600 mg/day. Users who escalated intake typically step down by 200 mg every 3–7 days to limit rebound fatigue.
• Cycling: Cycling is common practice to limit perceived tolerance, for example 4 weeks on and 2 weeks off, or 5 days on and 2 off. No study has tested whether cycling preserves efficacy.

Sourcing and Quality

• Pharmaceutical products: Arcalion (Laboratoires Servier, 200 mg tablets) and Enerion are regulated medicines in France and some other countries, manufactured to pharmaceutical standards; they are the most reliable sources.
• U.S. supplement market: Sulbutiamine is on the U.S. Food and Drug Administration (FDA) Dietary Supplement Ingredient Advisory List, so U.S. supplement products sit in a legal gray zone with no manufacturing oversight specific to this ingredient.
• Third-party testing: A batch certificate of analysis showing high-performance liquid chromatography purity of at least 98%, plus heavy-metal and microbial testing, is the minimum quality signal; ConsumerLab has not tested any sulbutiamine product.
• Proprietary blends: Sulbutiamine often appears in pre-workout, fat-burner and “focus” blends alongside stimulants such as higenamine or hordenine (Operation Supplement Safety); single-ingredient products avoid hidden co-ingredients.
• Label names: Products may list sulbutiamine as bisibutiamine, sulbutiamina, O-isobutyrylthiamine disulfide or Arcalion.
• Stability and storage: Sulbutiamine degrades under acid, alkaline, oxidative and light stress but withstands dry heat (Farid & Abdelwahab, 2016); storage in sealed containers away from light and humidity preserves potency.

Practical Considerations

• Time to effect: Users report alertness within hours; the only controlled fatigue signal appeared at day 7 and faded by day 28 (Tiev et al., 1999). Nerve-function (Kiew et al., 2002) and multiple sclerosis fatigue (Sevim et al., 2017) changes were measured after 6–8 weeks.
• Common pitfalls: Frequent mistakes include confusing sulbutiamine with benfotiamine, evening dosing that disrupts sleep, combining it with other stimulants, escalating doses beyond 600 mg/day, and expecting an antidepressant effect, which the depression trial (Lôo et al., 2000) did not show.
• Regulatory status: A prescription or over-the-counter medicine in France and several other countries; not approved in the United States, on the FDA advisory list since December 2019, and prohibited for U.S. service members. Not on the World Anti-Doping Agency Prohibited List.
• Cost and research incentives: Sulbutiamine is inexpensive and off-patent, but U.S. access is limited. No manufacturer, insurer or health system has a financial incentive to fund large new trials, which partly explains the thin modern evidence base.

Interaction with Foundational Habits

• Sleep: Blunting interaction. Its wake-promoting effect, seen as more wakefulness and lighter sleep in monkeys (Balzamo & Vuillon-Cacciuttolo, 1982), can delay sleep onset. Morning dosing and monitoring sleep latency limit this; it may help daytime alertness after poor sleep but does not replace sleep.
• Nutrition: Indirect, potentiating interaction. It supplies thiamine to the brain, which matters most with high refined-carbohydrate intake, alcohol use or low whole-grain and legume intake. Raw fish and heavy tea or coffee reduce ordinary thiamine availability; a fat-containing meal may aid absorption.
• Exercise: Indirect interaction. Thiamine is needed to burn carbohydrate for energy, and athletes use sulbutiamine for its mild stimulant effect, but no trial shows improved performance, strength or endurance. Tested athletes face screening confusion with steroid metabolites.
• Stress management: Indirect interaction. It reduced drive-related disability during depression treatment (Lôo et al., 2000) but showed no antidepressant or cortisol-lowering effect. It does not substitute for stress-reduction practices; agitation at higher doses can worsen perceived stress.

Monitoring Protocol & Defining Success

Baseline testing before a first course establishes thiamine status, kidney and liver function, and a psychiatric and sleep history, so that benefit can be judged against a personal starting point and people at risk of mood or sleep problems are identified. A validated fatigue questionnaire and a two-week sleep log at baseline give the qualitative reference point.

Ongoing monitoring follows a set cadence: a symptom and sleep check at 1 week, a repeat fatigue questionnaire at 4 weeks, and repeat thiamine and kidney labs at the end of each course or every 6–12 months for repeated courses. Success means a meaningful drop in fatigue scores, sustained daytime alertness, and unchanged sleep and mood. Absence of benefit by 4–8 weeks marks non-response.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Whole-blood thiamine diphosphate	120–180 nmol/L	Thiamine status	Conventional range about 70–180 nmol/L; functional practitioners target the upper half. Fasting not required; protect sample from light.
Erythrocyte transketolase activity coefficient (ETKAC)	Below 1.15	Functional thiamine sufficiency	ETKAC: red-cell enzyme test of thiamine activity; 1.15–1.25 marginal, above 1.25 deficient. Pair with thiamine diphosphate.
Red blood cell magnesium	5.0–6.5 mg/dL	Magnesium is needed to activate thiamine	Conventional range about 4.2–6.8 mg/dL; serum magnesium misses tissue deficiency.
eGFR and creatinine	eGFR above 90 mL/min/1.73 m²	Kidneys clear thiamine metabolites	eGFR: estimated glomerular filtration rate, kidney filtering estimate. Conventional normal is above 60; morning, well-hydrated sample.
ALT	Below 25 U/L	Liver safety check	ALT: alanine aminotransferase, a liver enzyme. Conventional upper limit about 40–55 U/L; avoid heavy exercise 48 hours before.
Fasting glucose and HbA1c	Glucose 75–90 mg/dL; HbA1c below 5.4%	Diabetes drives thiamine loss and neuropathy	HbA1c: 3-month average blood sugar. Conventional normal glucose below 100 mg/dL and HbA1c below 5.7%; 8–12 hour fast.
Nerve conduction study (if neuropathy)	No established target; track change from own baseline	Objective nerve function	Only for diagnosed polyneuropathy; repeat after 6–8 weeks under a neurologist.

Qualitative markers:

• Daytime energy and fatigue, rated weekly on the Fatigue Severity Scale (a validated 9-item questionnaire)
• Mental clarity, focus and motivation during demanding tasks
• Sleep onset time, night waking and morning refreshment from a sleep log
• Mood stability, including irritability, racing thoughts or reduced need for sleep (warning signs)
• Urge to increase the dose or difficulty skipping doses

Emerging Research

• Pediatric bedwetting trial: NCT06497647, “New Treatment for Nocturnal Enuresis in Children”, randomized 450 children to sulbutiamine, imipramine or both; registry status is unknown, but results were published in 2026 (Ahmed Mahmoud et al., 2026). It is the only registered sulbutiamine trial.
• No adult trials registered: A September 2026 ClinicalTrials.gov search found no registered trial of sulbutiamine for fatigue, cognition or aging in adults, so the conflicting fatigue evidence is unlikely to be resolved soon.
• Stroke neuroprotection: A computational drug-repurposing screen identified sulbutiamine as blocking PDK2 (pyruvate dehydrogenase kinase 2, an enzyme that throttles mitochondrial fuel use) and protecting rat brains after stroke (Meng et al., 2025); human testing would strengthen the case.
• Sulfur-based antioxidant pharmacology: Thiamine disulfides are reduced by the thioredoxin and glutathione systems and switch on Nrf2 antioxidant genes (Folda et al., 2025), suggesting effects beyond vitamin B1 supply.
• Diabetic complications: Rat studies report kidney (Ghaiad et al., 2023) and testicular (Abdelmonem et al., 2024) protection, extending the human neuropathy signal but untested in people.
• Evidence weakening the case: The null placebo-controlled fatigue trial (Tiev et al., 1999) and the failure to shrink tumors in mice (Jonus et al., 2020) temper enthusiasm; a 2020 review calls for new randomized trials (Starling-Soares et al., 2020).

Conclusion

Sulbutiamine is a fat-soluble, laboratory-made form of vitamin B1 that reaches the brain more readily than ordinary vitamin B1. Once a prescription remedy for persistent weakness in France, it is now also sold online for focus and energy, though its legal status as a supplement is questioned in the United States.

For health-focused adults, the most consistent human signals are modest: better memory and daily function when added to standard Alzheimer’s treatment, better nerve signaling in diabetic nerve damage, and faster recovery of drive during depression treatment. Each rests on a single small trial. Its best-known use, relief of fatigue, is the most disputed: reports without a placebo group are positive, while the strongest placebo-controlled trial found no lasting effect. Brain protection, antioxidant effects and protection against diabetic organ damage have so far been shown only in cells and animals.

Short courses appear well tolerated, with mild stomach upset, headache and occasional sleep disruption. The clearest concerns are mood swings and compulsive use in people with bipolar disorder, confusion on sports drug tests, and a lack of data beyond a few months.

The evidence base is old, small and partly produced during the drug’s commercial marketing, including studies its own authors described as commercial. The United States military supplement-safety program and the Food and Drug Administration, which have no commercial stake, flag uncertainty rather than proven harm. Overall, sulbutiamine’s value for long-term health remains uncertain.

Top - Benefits - Risks - Protocol